Clinical Trials on Plaque-Type Psoriasis

Total 59223 results

Novartis Pharmaceuticals

Completed

A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME) (SUPREME)

Plaque Type Psorisis

Italy
Centre of Evidence of the French Society of Dermatology

Recruiting

Systemic Treatment of Moderate-to-severe Psoriasis in Adults: Update of the French Guidelines

Psoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis Pustular

France
UCB Biopharma SRL

Completed

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE READY)

Psoriatic Arthritis | Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, United Kingdom
Fresenius Kabi SwissBioSim GmbH
Merck KGaA, Darmstadt, Germany

Completed

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis (AURIEL-PsO)

Psoriasis | Moderate to Severe Plaque Psoriasis | Plaque Type Psoriasis

United States, Canada, Czechia, Hungary, Russian Federation, Bulgaria, Mexico, United Kingdom, Poland, Germany, Estonia, France
Amgen

Completed

Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis

Psoriasis-Type Psoriasis | Plaque-Type Psoriasis

United States
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE VIVID)

Psoriatic Arthritis | Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Poland, Russian Federation, United Kingdom
University of Pennsylvania
Patient-Centered Outcomes Research Institute; University of Utah; National Psoriasis...

Completed

Light Treatment Effectiveness (LITE) Study (LITE)

Psoriasis | Psoriatic Plaque

United States
KoBioLabs

Active, not recruiting

A Study to Investigate Efficacy and Safety of KBL697 in Patients With Moderate Plaque Type Psoriasis

Psoriatic Plaque

United States, Australia
Escalier Biosciences B.V.
Innovaderm Research Inc.

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Topical ESR-114 in Subjects With Plaque Psoriasis

Psoriatic Plaque

United States, Canada
Pantec Biosolutions AG

Unknown

Laser-assisted Topical Administration of Etanercept (Enbrel®) in Patients With Mild to Moderate Plaque-type Psoriasis

Psoriatic Plaque

Switzerland
ProgenaBiome

Recruiting

A Pilot Study to Explore the Role of Gut Flora in Psoriasis

Psoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis Geographica

United States
Novartis Pharmaceuticals

Completed

Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients

Psoriasis, Plaque-type Psoriasis

United States
UCB Biopharma SRL

Recruiting

A Study to Evaluate the Efficacy, Safety, and Drug Concentration of Certolizumab Pegol (CZP) in Children and Adolescent Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO) (CIMcare)

Moderate Chronic Plaque Psoriasis | Severe Chronic Plaque Psoriasis | Mixed Guttate/Plaque Psoriasis

United States, Canada, Puerto Rico
Novartis Pharmaceuticals

Completed

A Worldwide Survey on the Understanding of Psoriatic Disease Among Patients With Psoriasis and Psoriatic Arthritis

Plaque Psoriasis, Psoriatic Arthritis

Switzerland
Galderma R&D

Completed

Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis

Plaque-type Psoriasis

United States
Deltanoid Pharmaceuticals

Completed

Study of Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis

Plaque-type Psoriasis

United States
Pfizer

Completed

Safety Study of Ointment for the Treatment of Plaque-type Psoriasis (AN2728-PSR-104)

Plaque-type Psoriasis

Australia
TetraLogic Pharmaceuticals

Completed

SHP-141C in Plaque Type Psoriasis

Plaque Type Psoriasis

Australia
Mitsubishi Tanabe Pharma Corporation

Completed

A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis

Plaque Psoriasis | Psoriatic Arthritis | Psoriatic Erythroderma | Pustular Psoriasis (Excluding a Localized)

Japan
Amgen

Completed

Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)

Psoriasis | Plaque-type Psoriasis

United States, Canada
Stiefel, a GSK Company
GlaxoSmithKline

Completed

A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis

Plaque-Type Psoriasis

United States
Egymedicalpedia

Not yet recruiting

Evaluation of TWEAK in Plaque Psoriasis and Psoriatic Arthritis Patients

Plaque Psoriasis

Egypt
Sun Pharmaceutical Industries Limited

Withdrawn

A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)

Plaque-type Psoriasis
Novartis Pharmaceuticals

Completed

AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis

Plaque-type Psoriasis

Germany, United States, Japan, France, Norway, Israel, Iceland
Sandoz
Hexal AG

Completed

Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira (ADACCESS)

Plaque Type Psoriasis

United States, France, Bulgaria, Slovakia
Novartis Pharmaceuticals

Not yet recruiting

Modifying PEST for Psoriatic Arthritis Screening (ScreenX)

Plaque Psoriasis | Psoriatic Arthritis
Eli Lilly and Company

Active, not recruiting

A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India

Plaque Psoriasis | Psoriatic Arthritis

India
Idera Pharmaceuticals, Inc.

Completed

Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis | Actively Extending Plaque Psoriasis

United States
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE SURE)

Moderate to Severe Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Taiwan
Wake Forest University

Completed

Thalidomide in the Treatment of Chronic Plaque Psoriasis.

Psoriasis, Plaque-type

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis (STATURE)

Plaque-type Psoriasis

United States, Austria, Germany, France, Japan, Canada, Slovakia, India
Aurigene Discovery Technologies Limited

Completed

A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis (INDUS-2)

Chronic Plaque-type Psoriasis

India
Novartis Pharmaceuticals

Completed

Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis

Chronic Plaque-type Psoriasis

United States
Novartis Pharmaceuticals

Completed

Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis

Chronic Plaque Type Psoriasis

Germany, United States, Belgium, Korea, Republic of, Spain, Taiwan, Australia, Austria, Italy, Estonia, Israel, Bulgaria, Netherlands, France, Switzerland, Portugal, Slovakia, Norway, United Kingdom, Hungary, Turkey, Canada, Denmark, ...
Novartis Pharmaceuticals

Completed

AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis

Chronic Plaque-type Psoriasis

Germany, United States, Japan, France, Israel, Norway, Iceland
Novartis Pharmaceuticals

Completed

A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Chronic Plaque-type Psoriasis

United States, Estonia, Japan, Latvia, Canada, Iceland
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE BRIGHT)

Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Taiwan, United Kingdom
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE RADIANT)

Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Belgium, Canada, France, Germany, Netherlands, Poland, Spain, Turkey, United Kingdom
Biocon Biologics Inc.
MEDA Pharma GmbH & Co. KG; Mylan Inc.; IQVIA Pvt. Ltd

Completed

Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity

Moderate Chronic Plaque Psoriasis | Severe Chronic Plaque Psoriasis

Bulgaria, Czechia, Estonia, Poland
UCB Biopharma SRL

Completed

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)

Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Canada
Novartis Pharmaceuticals

Completed

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

Chronic Severe Plaque-type Psoriasis

Belgium, Italy, Egypt, France, Hungary, Russian Federation, Germany, Israel, Spain, Japan, Estonia, United Kingdom, Poland, Colombia, United States, Latvia, Guatemala, Romania, Switzerland
UCB Biopharma SRL

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis (BE SHINING)

Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

China
Novartis Pharmaceuticals

Completed

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

Moderate to Severe Plaque-type Psoriasis

Germany, United States, Belgium, Colombia, Spain, Estonia, Hungary, Japan, Lithuania, Taiwan, Australia, Korea, Republic of, Canada, Singapore, Italy, Israel, Sweden, Guatemala, United Kingdom, Argentina, France, Poland, Latvia, Iceland, Finla... and more
Novartis Pharmaceuticals

Completed

First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks (FEATURE)

Moderate to Severe Plaque-type Psoriasis

Germany, United States, Estonia, France, Canada
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens (SCULPTURE)

Moderate to Severe Plaque-type Psoriasis

United States, Czech Republic, Austria, Germany, India, Japan, Bulgaria, Singapore, Switzerland, United Kingdom, Italy, France, Poland, Slovakia, Canada, Vietnam
Novartis Pharmaceuticals

Completed

Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE) (JUNCTURE)

Plaque-type Psoriasis

Germany, United States, France, Estonia, Canada
Novartis Pharmaceuticals

Completed

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Moderate to Severe Chronic Plaque-Type Psoriasis

United States, Germany, Japan, Bulgaria, Czechia, Singapore, Switzerland, United Kingdom, Italy, France, Vietnam, Poland, Slovakia, Austria, Canada
Novartis Pharmaceuticals

Completed

Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab (ARROW)

Chronic Plaque-type Psoriasis

Germany, United States, Canada
Soligenix

Recruiting

Topical SGX302 for Mild-to-Moderate Psoriasis

Psoriasis | Plaque Psoriasis | Psoriasis Vulgaris

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year (ERASURE)

Moderate to Severe Plaque-type Psoriasis

United States, Colombia, Estonia, Japan, Taiwan, Israel, Canada, Lithuania, Argentina, Latvia, Iceland, Mexico

Clinical Trials on Plaque-Type Psoriasis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations